[Windflier]

A supposedly miracle cure ... "could one day be used..."

In't that always the story with these kinds of discoveries?

[Democrat_media]

looks good ,Bookmark

[Jack Hydrazine]

We Used to Recycle Drugs From Patients’ Urine
http://www.smithsonianmag.com/smart-news/we-used-recycle-drugs-patients-urine-180953789/?no-ist

[GilesB]

“The discovery of this novel compound challenges long-held scientific beliefs ...”

THAT sounds like “settled science”! Why is anybody allowed to question the “settled science” that superbugs cannot be killed??

The debate is over, isn’t it? These people are preaching voodoo magic and should be banned!! They are not scientist if they don’t accept “settled science”, are they?

[Vince Ferrer]

Stop it. The science is settled.

[T-Bone Texan]

I recently read a synopsis of a study wherein they found that combining Colloidal Silver with antibiotics made the antibiotics about 1000 times more effective than the antibiotics alone.

I am a recent convert to Colloidal Silver. It certainly works on my dogs' and cats' skin conditions.

I asked my doc about it and he had never heard of it.

[Straight Vermonter]

With regard to resistance this is what another article says about this discovery:

The researchers are too glowingly optimistic about the likelihood of resistance emerging, I believe. In fact, the compound is being touted as “resistant to resistance” based on lab testing. Bacteria are always smarter than the people who develop and use them. While it may have taken 30+ years for Vancomycin resistance to develop, in part that is likely because we didn’t use that much of it until the last decade. Now we regularly see VISA organisms, with reduced susceptibility to Vancomycin and occasionally a totally Vanc resistant isolate.

For Vanc resistance, we now often turn to Daptomycin. Discovered in soil from Mt. Ararat, Turkey, Cubist got FDA approval for Daptomycin in 2003.⁠ In contrast to the slow resistance with Vancomycin, a case of Daptomycin resistant S. aureus bacteremia⁠ (blood stream infection) was reported in 2005. This past summer, I saw Dapto resistance emerge, similarly in patients with inadequately drained foci of infection.

Similarly, Linezolid resistance in MRSA was noted in 2001, only a year after approval. It had been seen in an Enterococcus faecium infection in 1999, even before approval.

My biggest concern, should Teixobactin make it to market, is that it will be squandered as every other good new antibiotic has been, and so resistance will rapidly emerge as the drug is overused. I have particularly been disappointed to see this with the other novel antibiotics developed during my career—Linezolid (Pfizer) and Daptomycin. I see both marketed irresponsibly (including promoting use to Social Service case workers) because they are convenient to use. Medicare has not been willing to pay for home IV antibiotics, so many of us use Daptomycin, which can be given once-daily in an outpatient clinic, so that our patients won’t have to go to a nursing home to receive antibiotics. As a result, we’re creating bacteria resistant to one of our few remaining effective antibiotics. Similarly, Linezolid is wasted for convenience, since it can be given orally; it has also been promoted for inappropriate uses, as treating colonization in wounds or in nursing home patients, rather than infection.